Optometry’s role in the opioid epidemic

Article

I have heard doctors of various specialties refer to their Drug Enforcement Agency (DEA) license fees as no more than taxes and prescription drug monitoring programs as government overreach. It is true that when my DEA license is about to expire, I wish the renewal fee was a few hundred dollars less. However, I do realize all that goes into my privilege to judiciously prescribe controlled substances for acute pain to the eye and adnexa.

Related: 3 points to consider when prescribing narcotics

As for prescription drug monitoring programs, ODs in Georgia with DEA licenses had to register by January 2019, and I could not agree more that these programs are necessary and even essential to curb drug overdoses in the U.S.

CDC report
In December 2018, the Centers for Disease Control and Prevention (CDC) published a report on drug overdose deaths in the U.S. between 2011 and 20161 which contained, among other metrics, the most common drugs involved.

Previously by Dr. Casella: Make one decision per week to improve the practice

Not surprisingly, fentanyl, a synthetic opioid indicated for severe pain, was at the top of the list by being referenced in the death certificates of 28.8 percent of drug overdose deaths. Heroin and cocaine rounded out the top three, respectively.

ODs should have vested interest in these data, at the very least from the perspective of a concerned citizen. However, as the list of drugs continues, drugs that are commonly prescribed for acute eye pain are listed.

Hydrocodone ranks ninth on the list, referenced in 5 percent of drug overdose deaths in 2016. When a narcotic analgesic is indicated, hydrocodone is a drug of choice for many ODs. It is relatively cheap and readily available in fixed combination with non-narcotic analgesics. It also works quite well at controlling severe pain, say, from a geographic corneal abrasion.

Rxing hydrocodone
In fact, hydrocodone is so popular in primary eye care that, when it was moved from Schedule 3 to Schedule 2 by the FDA several years ago, numerous state optometry associations passed so-called “hydrocodone fix” legislation (Georgia included). These laws allowed ODs to continue prescribing hydrocodone in states in which Schedule 2 drugs were not on their formularies.

Read more Optometry Times editorials here

I encourage everyone to read the report. I teach a continuing education course on drug diversion, and I have incorporated these data into my curriculum. As more data becomes available, the hope is that the statistics from the CDC will show a steep curbing of the drug overdose epidemic in the U.S.

The prescribing of such medications is an earned privilege, and with it comes a seat at a table that is currently charged with the task of curbing the epidemic of drug overdose.

Read more by Dr. Casella

References:

1. Hedegaard HH, Bastian, BA, Trinidad JP, Spencer M, Warner, M. Drugs Most Frequently Involved in Drug Overdose Deaths: United States, 2011–2016. National Vital Statistics Reports. 2018 Dec;67(9). Available at: https://www.cdc.gov/nchs/data/nvsr/nvsr67/nvsr67_09-508.pdf. Accessed 1/11/19.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.